ZA200608016B - Adjuvant for the enhancement of the efficacy of vaccines - Google Patents

Adjuvant for the enhancement of the efficacy of vaccines

Info

Publication number
ZA200608016B
ZA200608016B ZA200608016A ZA200608016A ZA200608016B ZA 200608016 B ZA200608016 B ZA 200608016B ZA 200608016 A ZA200608016 A ZA 200608016A ZA 200608016 A ZA200608016 A ZA 200608016A ZA 200608016 B ZA200608016 B ZA 200608016B
Authority
ZA
South Africa
Prior art keywords
acid
adjuvant
antigen
group
provides
Prior art date
Application number
ZA200608016A
Other languages
English (en)
Inventor
Grobler Anne Frederica
Kotze Abraham Frederik
Original Assignee
Univ Northwest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwest filed Critical Univ Northwest
Priority to ZA200608016A priority Critical patent/ZA200608016B/xx
Publication of ZA200608016B publication Critical patent/ZA200608016B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA200608016A 2005-01-28 2006-09-27 Adjuvant for the enhancement of the efficacy of vaccines ZA200608016B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA200608016A ZA200608016B (en) 2005-01-28 2006-09-27 Adjuvant for the enhancement of the efficacy of vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200500856 2005-01-28
ZA200608016A ZA200608016B (en) 2005-01-28 2006-09-27 Adjuvant for the enhancement of the efficacy of vaccines

Publications (1)

Publication Number Publication Date
ZA200608016B true ZA200608016B (en) 2008-09-25

Family

ID=36608667

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608016A ZA200608016B (en) 2005-01-28 2006-09-27 Adjuvant for the enhancement of the efficacy of vaccines

Country Status (11)

Country Link
US (2) US20090010964A1 (xx)
EP (1) EP1843787B1 (xx)
JP (1) JP5159322B2 (xx)
CN (1) CN101123982B (xx)
AT (1) ATE531389T1 (xx)
CA (1) CA2596920C (xx)
DK (1) DK1843787T3 (xx)
ES (1) ES2375267T3 (xx)
HK (1) HK1118013A1 (xx)
WO (1) WO2006079989A2 (xx)
ZA (1) ZA200608016B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123982B (zh) 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
US20100297249A1 (en) * 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018225785A1 (ja) * 2017-06-06 2018-12-13 株式会社Ａｔｏｍｉｓ ワクチン組成物
US11298380B2 (en) 2018-01-02 2022-04-12 Khloris Biosciences, Inc. IPSC-based vaccine as a prophylactic and therapeutic treatment for cancer
EP4346886A1 (en) 2021-06-01 2024-04-10 Khloris Biosciences, Inc. Induced pluripotent stem cell-based cancer vaccines
CN116139266B (zh) * 2023-04-14 2023-07-14 清华大学 长链不饱和脂肪酸在制备用于灭活疫苗的免疫增强剂中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB425406A (en) * 1933-06-07 1935-03-07 Vincent Gregory Walsh Improvements in or relating to the manufacture of medical preparations of bacterial toxins
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH04279523A (ja) * 1991-01-11 1992-10-05 Nisshin Flour Milling Co Ltd 免疫賦活油脂加工品
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
JPH06247849A (ja) * 1993-02-25 1994-09-06 Kao Corp 免疫増強剤
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
JPH09121766A (ja) * 1995-10-31 1997-05-13 Meiji Milk Prod Co Ltd ｎ−６系列／ｎ−３系列脂肪酸比率 を調整した乳児用食品
CA2237306C (en) * 1995-11-13 2008-10-07 Pitmy International N.V. Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
US6696089B2 (en) * 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
JP2001029010A (ja) * 1999-07-26 2001-02-06 Snow Brand Milk Prod Co Ltd 栄養組成物
JP2001245686A (ja) * 1999-12-27 2001-09-11 Osaka City 脂肪酸低級アルコールエステルの製造方法
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
CA2416519C (en) * 2000-07-19 2011-09-20 Pitmy International N.V. Transportation of nucleic acid substances
CN100531799C (zh) * 2000-07-19 2009-08-26 西北大学 增强抗感染剂作用的制剂和方法
US7033813B2 (en) * 2001-09-05 2006-04-25 Trevor P Castor Inactivated vaccines for aids and other infectious diseases
CN1391954A (zh) * 2002-07-09 2003-01-22 新疆大学生命科学与技术学院 增强核酸疫苗免疫的组合物及其生产方法和使用方法
CN101123982B (zh) 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂

Also Published As

Publication number Publication date
HK1118013A1 (en) 2009-01-30
DK1843787T3 (da) 2012-02-20
CA2596920C (en) 2015-05-05
ES2375267T3 (es) 2012-02-28
US20090010964A1 (en) 2009-01-08
WO2006079989A3 (en) 2006-10-12
EP1843787B1 (en) 2011-11-02
WO2006079989A2 (en) 2006-08-03
EP1843787A2 (en) 2007-10-17
US20140178431A1 (en) 2014-06-26
CN101123982B (zh) 2015-06-17
ATE531389T1 (de) 2011-11-15
JP2008528570A (ja) 2008-07-31
CA2596920A1 (en) 2006-08-03
CN101123982A (zh) 2008-02-13
US9585955B2 (en) 2017-03-07
JP5159322B2 (ja) 2013-03-06

Similar Documents

Publication Publication Date Title
HK1118013A1 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
NZ608755A (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
WO2002005851A8 (en) Enhancement of the action of central and peripheral nervous system agents
US11648229B2 (en) Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
Abed et al. Synthesis of 1, 3-dioleoyl-2-arachidonoylglycerol-rich structured lipids by lipase-catalyzed acidolysis of microbial oil from Mortierella alpina
KR20070104596A (ko) 크립테코디늄 속으로 부터의 항산화 추출물의 생산 및 용도
ATE384518T1 (de) Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
US20130317241A1 (en) Process for concentrating omega-3 fatty acids
WO2002005850A3 (en) Enhancement of the action of anti-infective agents
CN113438948A (zh) 极长链脂肪酸组合物
AR076184A1 (es) Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.
Patel et al. Novel biorefinery approach aimed at vegetarians reduces the dependency on marine fish stocks for obtaining squalene and docosahexaenoic acid
PL366696A1 (en) Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
No et al. Pinolenic acid as a new source of phyto‐polyunsaturated fatty acid
JP2007089522A5 (xx)
JP2022009143A (ja) 住血吸虫症を予防かつ／または治療するための組成物および方法
JP2004168985A (ja) ω−３系高度不飽和脂肪酸含有部分グリセリド組成物及びその製造方法
KR20070122059A (ko) 인지질 조성물 및 인지질 조성물 제조방법
JPWO2020050304A1 (ja) リパーゼ加水分解反応を用いるドコサヘキサエン酸含有グリセリドの製造方法
van den Elsen et al. SIX
JP2018127511A (ja) 脂質組成物、その用途及びその製造方法
van den Elsen et al. SEVEN
JP2011020978A (ja) 免疫増強剤